248 related articles for article (PubMed ID: 11713591)
1. Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma.
Ritz U; Momburg F; Pilch H; Huber C; Maeurer MJ; Seliger B
Int J Oncol; 2001 Dec; 19(6):1211-20. PubMed ID: 11713591
[TBL] [Abstract][Full Text] [Related]
2. Functional deficiencies of components of the MHC class I antigen pathway in human tumors of epithelial origin.
Delp K; Momburg F; Hilmes C; Huber C; Seliger B
Bone Marrow Transplant; 2000 May; 25 Suppl 2():S88-95. PubMed ID: 10933198
[TBL] [Abstract][Full Text] [Related]
3. Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer.
Seliger B; Stoehr R; Handke D; Mueller A; Ferrone S; Wullich B; Tannapfel A; Hofstaedter F; Hartmann A
Cancer Immunol Immunother; 2010 Apr; 59(4):529-40. PubMed ID: 19820934
[TBL] [Abstract][Full Text] [Related]
4. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome.
Meissner M; Reichert TE; Kunkel M; Gooding W; Whiteside TL; Ferrone S; Seliger B
Clin Cancer Res; 2005 Apr; 11(7):2552-60. PubMed ID: 15814633
[TBL] [Abstract][Full Text] [Related]
5. Coordinate downregulation of multiple MHC class I antigen processing genes in chemical-induced murine tumor cell lines of distinct origin.
Seliger B; Wollscheid U; Momburg F; Blankenstein T; Huber C
Tissue Antigens; 2000 Oct; 56(4):327-36. PubMed ID: 11098932
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts.
Seliger B; Harders C; Lohmann S; Momburg F; Urlinger S; Tampé R; Huber C
Eur J Immunol; 1998 Jan; 28(1):122-33. PubMed ID: 9485192
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the MHC class I antigen presentation machinery in human embryonal carcinomas: evidence for deficiencies in TAP, LMP and MHC class I expression and their upregulation by IFN-gamma.
Seliger B; Dunn T; Schwenzer A; Casper J; Huber C; Schmoll HJ
Scand J Immunol; 1997 Dec; 46(6):625-32. PubMed ID: 9420627
[TBL] [Abstract][Full Text] [Related]
8. Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation.
Seliger B; Atkins D; Bock M; Ritz U; Ferrone S; Huber C; Störkel S
Clin Cancer Res; 2003 May; 9(5):1721-7. PubMed ID: 12738726
[TBL] [Abstract][Full Text] [Related]
9. MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components.
Garcia-Lora A; Martinez M; Algarra I; Gaforio JJ; Garrido F
Int J Cancer; 2003 Sep; 106(4):521-527. PubMed ID: 12845647
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma?
Atkins D; Ferrone S; Schmahl GE; Störkel S; Seliger B
J Urol; 2004 Feb; 171(2 Pt 1):885-9. PubMed ID: 14713847
[TBL] [Abstract][Full Text] [Related]
11. Impaired expression of proteasome subunits and human leukocyte antigens class I in human colon cancer cells.
Miyagi T; Tatsumi T; Takehara T; Kanto T; Kuzushita N; Sugimoto Y; Jinushi M; Kasahara A; Sasaki Y; Hori M; Hayashi N
J Gastroenterol Hepatol; 2003 Jan; 18(1):32-40. PubMed ID: 12519221
[TBL] [Abstract][Full Text] [Related]
12. Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6.
Maeurer MJ; Gollin SM; Storkus WJ; Swaney W; Karbach J; Martin D; Castelli C; Salter R; Knuth A; Lotze MT
Clin Cancer Res; 1996 Apr; 2(4):641-52. PubMed ID: 9816214
[TBL] [Abstract][Full Text] [Related]
13. Identification of miR-200a-5p targeting the peptide transporter TAP1 and its association with the clinical outcome of melanoma patients.
Lazaridou MF; Gonschorek E; Massa C; Friedrich M; Handke D; Mueller A; Jasinski-Bergner S; Dummer R; Koelblinger P; Seliger B
Oncoimmunology; 2020 Jun; 9(1):1774323. PubMed ID: 32923135
[TBL] [Abstract][Full Text] [Related]
14. In situ analysis of the antigen-processing machinery in acute myeloid leukaemic blasts by tissue microarray.
Hoves S; Aigner M; Pfeiffer C; Laumer M; Obermann EC; Mackensen A
Leukemia; 2009 May; 23(5):877-85. PubMed ID: 19148137
[TBL] [Abstract][Full Text] [Related]
15. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.
Meissner M; Whiteside TL; van Kuik-Romein P; Valesky EM; van den Elsen PJ; Kaufmann R; Seliger B
Br J Dermatol; 2008 May; 158(5):930-40. PubMed ID: 18284388
[TBL] [Abstract][Full Text] [Related]
16. Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors.
Facoetti A; Nano R; Zelini P; Morbini P; Benericetti E; Ceroni M; Campoli M; Ferrone S
Clin Cancer Res; 2005 Dec; 11(23):8304-11. PubMed ID: 16322289
[TBL] [Abstract][Full Text] [Related]
17. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions.
Vitale M; Rezzani R; Rodella L; Zauli G; Grigolato P; Cadei M; Hicklin DJ; Ferrone S
Cancer Res; 1998 Feb; 58(4):737-42. PubMed ID: 9485029
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex in tumor cell lines.
Johnsen A; France J; Sy MS; Harding CV
Cancer Res; 1998 Aug; 58(16):3660-7. PubMed ID: 9721876
[TBL] [Abstract][Full Text] [Related]
19. Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma.
Mehta AM; Jordanova ES; Kenter GG; Ferrone S; Fleuren GJ
Cancer Immunol Immunother; 2008 Feb; 57(2):197-206. PubMed ID: 17622526
[TBL] [Abstract][Full Text] [Related]
20. Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors.
Cabrera CM; Jiménez P; Cabrera T; Esparza C; Ruiz-Cabello F; Garrido F
Tissue Antigens; 2003 Mar; 61(3):211-9. PubMed ID: 12694570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
